| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6488962 | MALLINCKRODT INC | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
| US7976870 | MALLINCKRODT INC | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
Jun, 2027
(3 years from now) | |
| US8372432 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(4 years from now) | |
| US8668929 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(4 years from now) | |
| US8394408 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Mar, 2029
(4 years from now) | |
| US8377453 | MALLINCKRODT INC | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Nov, 2029
(5 years from now) | |
| US8980319 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(6 years from now) | |
| US8597681 | MALLINCKRODT INC | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
Dec, 2030
(6 years from now) | |
| US8741885 | MALLINCKRODT INC | Gastric retentive extended release pharmaceutical compositions |
May, 2032
(8 years from now) | |
| US9468636 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
| US9050335 | MALLINCKRODT INC | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
May, 2032
(8 years from now) | |
| US8992975 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
| US8658631 | MALLINCKRODT INC | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
May, 2032
(8 years from now) | |
Xartemis Xr is owned by Mallinckrodt Inc.
Xartemis Xr contains Acetaminophen; Oxycodone Hydrochloride.
Xartemis Xr has a total of 13 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xartemis Xr are:
- US6488962
Xartemis Xr was authorised for market use on 11 March, 2014.
Xartemis Xr is available in tablet, extended release;oral dosage forms.
Xartemis Xr can be used as management of acute pain in patients requiring opioid analgesia, method of treating patients with gastric retentive dosage form.
The generics of Xartemis Xr are possible to be released after 16 May, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 11, 2017 |
Drugs and Companies using ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Method of treating patients with gastric retentive dosage form; Management of acute pain in patients requiring opioid analgesia
Dosage: TABLET, EXTENDED RELEASE;ORAL
XARTEMIS XR family patents
